Venture capitalist Julie Grant argues against U.S. restrictions on China biotech investments

Venture capitalist Julie Grant opposes U.S. restrictions on biotech investments in China, arguing it would harm drug development and patients. Grant believes such measures are shortsighted and ignore decades of growing interdependency between U.S. and Chinese biotech industries. She contends that severing these ties would impede American progress. Legislators are considering adding biotechnology to industries covered by the COINS Act, which would allow federal scrutiny of U.S. investments in China's drug sector.